- Design
- Review of population pharmacokinetic analyses
- Population
- 20 FDA-approved small-molecule drugs for chronic inflammatory diseases
- Primary outcome
- Exposure (AUC) in patients vs healthy volunteers
- Effect
- 5 of 20 (25%) had AUC >25% higher in patients; all CYP3A4 or CYP2C19 substrates
This review in Clinical Pharmacology & Therapeutics examined population pharmacokinetic data for 20 small-molecule drugs approved by the FDA over 15 years for major chronic inflammatory indications, comparing exposure in patients with that in healthy volunteers.
Five of the 20 (25%) showed an AUC more than 25% higher in patients. All five are cleared mainly by CYP3A4 or CYP2C19, and for four, metabolism accounts for over half of elimination. The mechanism is long recognised: inflammatory cytokines such as IL-6 suppress several CYP enzymes.
The review is aimed at drug developers, but the mechanism matters at the bedside too. A patient with active inflammatory disease may handle a CYP3A4 substrate differently from the population in which its dose was set — and exposure can shift again when the inflammation is controlled, for instance after starting an IL-6 blocker.
- Expect higher exposure to some CYP3A4 and CYP2C19 substrates during active inflammation.
- Watch for toxicity from narrow-margin drugs such as tacrolimus, ciclosporin or voriconazole when inflammation flares.
- Anticipate falling levels of these drugs when inflammation is brought under control, including after starting an IL-6 inhibitor.
- Use drug-level monitoring where it exists to guide dosing through these transitions.
Why it matters
The patient's disease activity is itself a drug interaction, and it changes over time.
Don't overread it
This review covers 20 recently approved drugs and pharmacokinetics, not clinical harm; most drugs showed no meaningful difference.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free